Analysis of difficult problems on European Union laws and regulations of traditional herbal medicinal products / 中国中药杂志

Registration of Chinese patent medicine in European Union (EU) is of great significance to the internationalization of traditional Chinese medicine as EU market acts as an important position in the global botanical market. In retrospect, the domestic studies on EU regulations of traditional herbal medicinal products have been conducted for more than 10 years, but there is still some cognitive bias and lack of research. In this paper, a review of the relevant research progress and the main misunderstanding problems about Directive 2004/24/EC, like the centralized and decentralized supervision system of traditional herbal medicinal products in the EU, marketing authorization procedures for traditional herbal medicinal products, Community Herbal Monograph and List Entries, would be systematically analyzed, so as to provide reference for the registration of Chinese patent medicine in EU.

SCHWABE Company's patent portfolio of Ginkgo biloba preparation / 中国中药杂志

SCHWABE Company in German is the first and largest manufacturer of Ginkgo biloba preparation. The company not only has leading technology in this field, but also protects its own market effectively through the high quality of patent drafting and exactly patent layout. Based on multi-angle analysis for patent portfolio of G. biloba preparation at application time, legal status, globally layout, Chinese layout, the article provides technical reference of research and development of G. biloba, also provides valuable experience of traditonal Chinese medicine patent portfolio layout for Chinese enterprises.

Analysis on patent network of compound Danshen extracts built by Tasly / 中国中药杂志

Patent network of Chinese patent medicines is a patent group composed of several correlated patents around basic patents or core technologies characterized by traditional Chinese medicine technologies. With the clue of Tianjin Tasly Group's acquisition of seven compound Danshen patents characterized by extract feeds of Beijing Cairui Pharmaceutical Co., Ltd., we made an analysis on how Tasly builds a patent network themed on compound Danshen preparation products characterized by extract feeds, in hope of providing reference for other Chinese pharmaceutical enterprise to establish and improve key patent networks of traditional Chinese medicines.

Study on the complex prescription compatibility law of the cold and hot nature of Mahuang Decoction and its categorized formulae based on the cold-hot pad differentiating assay / 中国结合医学杂志

<p><b>OBJECTIVE</b>To explore the complex prescription compatibility law of the cold and hot nature of Mahuang Decoction (, MHD) and Maxing Shigan Decoction (, MXSGD), both categorized both categorized MHD) and Maxing Shigan Decoction (both categorized MXSGD), both categorized formulas but with different hot/cold natures.</p><p><b>METHODS</b>Oxygen consumption of mice was determined among three groups: MHD, MXSGD and the control; a cold-hot pad differentiating assay was used to observe the variability of temperature tropism among the groups of mice which was treated with MHD, MXSGD, and their compositions. Meanwhile, the total anti-oxidant capability (T-AOC) activity were detected.</p><p><b>RESULTS</b>After administration of MHD, the mice showed increased oxygen consumption (P<0.01). Compared with MHD group, the remaining rate of MXSGD mice on the hot pad was found to be significantly increased with the cold-hot pad differentiating assay (P<0.05). There was no significant difference (P>0.05) among the remaining rates of MXSGD, MXSGD with high dose Gypsum Fibrosum (MXHGF) group, and MXSGD with low dose Gypsum Fibrosum (MXLGF) group mice. Compared with the MHD group, T-AOC activity of the mice in the Consensus Compositons group was significantly decreased (P=0.0494). Compared with the MXSGD group, T-AOC activity of Gypsum Fibrosum (GF) group was increased significantly (P=0.0013).</p><p><b>CONCLUSIONS</b>The differences in cold and hot nature could be represented objectively between MHD with a hot nature and MXSGD with a cold nature. The reason may be the Gypsum Fibrosum which decreased the efficacy of the consensus compositions. However, increasing or decreasing the dose of Gypsum Fibrosum will not change the cold and hot nature of MXSGD.</p>

Influence of Pueraria thomsonii on insulin resistance induced by dexamethasone / 中国中药杂志

<p><b>OBJECTIVE</b>To investigate the influence of Pueraria thomsonii on insulin resistance induced by dexamethasone.</p><p><b>METHOD</b>3T3-L1 adipocytes model of insulin resistance was made by dexamethasone and the change of glucose concentration in cell culture was determined after action of drugs. Rat animal model of insulin resistance was made by intramuscular dexamethasone (1 mg x kg(-1), every other day), and fasting blood glucose (FBG) and fasting serum insulin (FINS) were enamined, and at the end of the experiment, insulin sensitive index (ISI) and insulin resistance index (IRI) were calculated.</p><p><b>RESULT</b>P. thomsonii decreased the concentration of glucose in 3T3-L1 adipocytes culture significantly and improved the sensitivity of 3T3-L1 adipocytes to insulin. P. thomsonii improved the sensitivity of rats to insulin and diminished the fasting serum insulin and insulin resistance index.</p><p><b>CONCLUSION</b>P. thomsonii can significantly improve insulin resistance induced by dexamethasone.</p>